Trelagliptin Size:Solid 2 mg 6S)-4-amino-5-hydroxy-4

6S)-4-amino-5-hydroxy-4

3(3):599-610

Chemical Name: N-(3-(dimethylamino)propyl)-4-(8-hydroxyquinolin-6-yl)benzamide

Pretreatment of cells with ODQ does not abolish this cell injury

Chemical Name: 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2

Trelagliptin Size:Solid 2 mg 6S)-4-amino-5-hydroxy-4Trelagliptin, also known as SYR 472, is a long acting dipeptidyl peptidase 4 (DPP 4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once weekly SYR 472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek()) was approved in